Aims: To examine the long-term effectiveness of lifestyle weight management interventions, recommended in clinical guidelines for patients with type 2 diabetes mellitus (T2DM) and obesity.
A lack of an evidence base for the longer-term clinical outcomes of non-surgical weight management in T2DM is a major barrier to both the public and insurance-based funding of suitable services. 11, 12 The LookAHEAD 13 randomized controlled trial included 5145 participants with T2DM, who were assigned to an intensive lifestyle intervention or to 3 sessions of diabetes support and education. The intervention was far more intensive than support generally available to patients with T2DM in the community, and included near-weekly individual or group sessions for 1 year and monthly sessions for the subsequent 4 years, along with optional meal replacements and a focus on high levels of supported physical activity. The results were impressive, with an 8.5% weight loss and a 7-mmol/mol reduction in glycated haemoglobin (HbA1c) after 1 year, attenuating to 4.7% and 2 mmol/mol after 4 years 13 ; however, selection bias is a potential issue for such an intensive trial, which had an entry criterion that included the ability to perform an exercise test; this may have resulted in a healthier and more adherent cohort than is seen in routine clinical care.
There is an urgent need, therefore, to improve the evidence base for the longer-term clinical outcomes of real-life non-surgical lifestyle weight management interventions in patients with T2DM. Evaluations of existing services [14] [15] [16] [17] [18] have shown modest results, with a minority of patients achieving clinically significant short-term weight loss. These interventions are low-cost and low-risk, however, with negligible ongoing costs if non-responding patients discontinue. It follows that if these interventions are effective in improving clinical outcomes for those with T2DM who do successfully lose weight, then they should become a much greater part of usual care, with investment in research to improve uptake and success.
The aims of the present study were to examine: (1) whether a sustainable non-surgical weight management intervention helps patients achieve a long-term 5% to 10% weight loss; (2) whether such weight loss improves glycaemic control; and (3) whether such weight loss reduces anti-glycaemic medication use. The clinical outcomes from nonsurgical weight management in the general diabetes patient population were established by using data from a large multidisciplinary weight management programme and routine diabetes care records. The use of routine data allowed efficacy for longer-term clinical outcomes to be established beyond the length of the weight management intervention, including the effect on glycaemic control and medication usage, while highlighting the important issues of uptake and adherence.
| METHODS
The National Health Service (NHS) Greater Glasgow and Clyde (GGC) These diabetes data were then combined with patients' records from the NHS GGC Weight Management Service (GCWMS), using the 
| Data handling
Data handling and exclusions are summarized in Figure 1 . All biochemical data were measured by routine NHS clinical laboratories. Where multiple values were recorded within a specific time window, the chronologically earliest was used. For those who were referred, if no weight data were recorded for a specific session, it was regarded as "not attended" for that session. Specific details on data handling for patients referred to, and those not referred to the GCWMS can be found in the File S1.
| Group definitions in the patients referred to GCWMS
Those who attended at least one session were labelled "attenders"
( Figure 1 ). Attenders were further divided into "non-completers"
(those who attended 1-6 sessions within phase 1) and "completers"
(those who attended at least 7/9 [80%] of the sessions within phase 1). We classified "unsuccessful completers" as those who attended at least 80% of sessions, but did not lose 5 kg (this was the definition used within the service and therefore affected the subsequent intervention), while "successful completers" attended at least 80% of sessions and achieved at least 5-kg weight loss by the end of phase 1.
| Statistical analyses
We compared reported means and SD values (for Gaussian variables), medians and interquartile ranges (for non-Gaussian continuous variables), and proportions where appropriate. We conducted tests of the null hypothesis between groups with independent t tests, ranksum tests, and χ 2 tests, respectively. Differences in continuous variables across time were assessed by taking the difference in individual measurements and conducting a one-sample t test. Difference in insulin use was defined as the net change in the proportion using insulin at different time points. Weight loss targets are often set at 5% (instead of 5 kg as in the GCWMS). Thus, for the sake of comparability, we additionally used a threshold of 5% of initial weight and reported 3-year change in HbA1c in these groups, thereby exploring the independent effect of the intention to treat in the GCWMS programme on glycaemic control.
To assess the effectiveness of successful completion of the The data used for this study are available to bona fide researchers via NHS Greater Glasgow and Clyde Safe Haven (http://www.nhsggc.
org.uk/about-us/professional-support-sites/nhsggc-safe-haven/)
3 | RESULTS
| Baseline characteristics by GCWMS status
We identified 23 208 patients with T2DM and co-existent obesity, with the required routine data for inclusion, residing in the GGC Health Board area of Scotland, and all potentially eligible to attend the GCWMS. In total, 3471 were referred to the service, and of these 1537 attended at least one session (44.3%), with 808 (23.3%) attending ≥7 sessions (completers). Of these, 336 patients (successful completers) went on to lose 5 kg in phase 1 of the programme (9.7% of all those referred; Figure 1 ).
The baseline characteristics of 19 737 patients who were not referred to the GCWMS, and 3471 who were referred and attended the service are shown in Table 1 . Those referred and attending were generally slightly younger and were more likely to be female, white, and were less likely to be socio-economically deprived (with 14.8% being defined as successful ( Table 2 ). The only significant difference between those individuals successfully completing and those who were unsuccessful completers, was a higher initial weight in those who were successful (116.6 AE 24.8 kg vs 113.2 AE 23.1 kg; P = .045).
| Changes in clinical variables over follow-up by GCWMS status
All comparator groups lost weight within the first year, but successful completers had the greatest weight loss after 1 year (−8.66 kg [95% CI −9.59 to −7.74]) and maintained this weight loss with weight change at year 3, relative to baseline, of −8.03 kg (95% CI −9.44 to −6.62; Table 3 and Figure 2 ).
Successful completers improved their glycaemic control in com-
parison to the other groups over the 3 years (Table 3 and Figure 2 ). successful and unsuccessful completers was similar to baseline level at 3 years.
The number of unique diabetes medications used increased gradually over 3 years in every group except the successful completers (Table 3 and Figure S1 ). Those who lost 5 kg in the GCWMS were >50% less likely to have been prescribed insulin at 1 and 2 years, although the effect was not significant at 3 years. Similar results were seen for the prescription of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, with successful completers~50% less likely to have been prescribed these medications at 3 years compared with unsuccessful and non-completers (Table S1 ).
To explore the GCWMS-specific effect of weight loss on HbA1c, the effect of 5% weight loss on change in HbA1c over 2 years, compared with baseline, was assessed within each of the GCWMS groups (not referred, non-completers and completers), adjusted for potential confounding variables (Table 5 ). The effect of 5% weight loss on change in HbA1c over 2 years was significant within each group but was largest in those who completed the programme (−2.49 [95% CI −3.53 to −1.46]; P < .001). The test for interaction comparing the effect of weight loss on HbA1c across groups was highly significant (P < .001).
Time spent in the weight management programme and changes in weight in both phase 1 and the whole programme, by completion status, are shown in Table 6 . Those who successfully completed phase 1 eventually spent a median (interquartile range) of 11.9 (7.10-17.3) months in the programme and lost a mean AE SD of 9.9 AE 8.24 kg by their final visit.
| DISCUSSION
In the present large study in patients with T2DM and obesity, using real-world data from a sustainable structured weight management intervention, we show those who attended and lost at least 5 kg in the first 16 weeks maintained that weight loss over 3 years. Patients who successfully lost 5 kg in the programme also had an independent, clinically significant reduction in HbA1c (6.6, 5.7 and 3.7 mmol/ mol at years 1, 2 and 3, respectively) compared with non-attenders and unsuccessful attenders. Successful completers of the weight management programme had a reduction in number of diabetes medications, and fewer successful completers progressed to requiring insulin. Only a small number of potentially eligible patients were referred, however, and fewer than half of those referred actually attended the service. Of those who attended ≥7 sessions, >40% achieved 5-kg weight loss. This research shows that a structured weight management programme can be clinically effective for at least some patients with T2DM; the main challenge is getting a higher number of patients referred to and engaging with intervention programmes.
Those patients who successfully lost 5 kg in the first 16 weeks of the programme went on to attend for an average of 11.9 months. This is probably related to the large weight loss and successful weight maintenance in that group and is supportive of current guidelines that recommend that patients receive monthly counselling for at least 1 year in order to better maintain weight loss. 20 The effects of weight loss on glycaemic control that we have found are very similar to those found by the National Institute of Health-funded LookA-HEAD study. 13 There are large differences between our study and LookAHEAD; the lookAHEAD intervention was far more intensive, it included supervised exercise and meal replacements, and the population included volunteer participants in a clinical trial. This is in contrast to real-world data from a completely free-of-charge weight management programme which may be a better representation of the general diabetes population. For those reasons, the LookAHEAD trial achieved weight loss in a far higher proportion of their partici-
pants, yet their weight loss effects on HbA1c were very similar, 13 with a change of −7 mmol/mol at year 1, attenuating to −2.8 mmol/ mol by year 3 compared with our −7.19 mmol/mol at year 1 and −1.86 mmol/mol by year 3. A recent small study based on real-life clinic data from Boston, Massachusetts, also showed similar results of attenuation of HbA1c reduction over time, despite maintenance of weight loss. 21 The mechanisms of this attenuation in HbA1c are unknown and possible explanations include improved medication adherence during the intervention period that decreases with time, or a difference in the metabolic response to acute weight loss as opposed to the maintenance of lower weight in the longer term.
What also remains unknown is the effect of this, albeit temporary, reduction in HbA1c on glucose-related diabetes endpoints, such as retinopathy, nephropathy and neuropathy, and also on the future trajectory of glycaemic control in those who lost weight compared with those who did not lose weight. If improved glycaemic control can be achieved against a background of less prescribed medication in those who lose weight, then that alone suggests that weight management interventions may be very cost-effective in patients with T2DM.
The obesity paradox is a phenomenon seen in observational studies whereby people with higher BMI experience better health outcomes compared with those with a BMI within the normal range . The obesity paradox has been described in a range of disease states, including T2DM. 22 Non-intentional weight loss is often cited as a potential source of bias in such analyses; that is, body mass being lower because of weight loss associated with a life-limiting illness or, as in the case of diabetes, weight loss attributable to poor glycaemic control. Our dataset allowed us to explore assumed intentionality of weight loss and its effect on HbA1c, and we found that 5% weight loss in those who attended weight management (and therefore assumed to be intentional weight loss) results in a greater reduction in The present study was based on data from electronic health records and therefore the major limiting issue is missing data. We applied strict criteria about the availability of key variables which would have been obtained through annual diabetes review, plus weight and age criteria to reduce the bias of misclassification of diabetes, and excluded 61.1% of those not referred to the GCWMS and 40.7% of those who were referred. Given that missing data are often attributable to a missed annual diabetes review, and therefore adverse health behaviour, it may be that there was a bias in the cohort towards a population with better overall diabetes management. It could be argued that this could affect the result in either direction, because of better adherence to the intervention or a smaller potential for improvement in glycaemic control.
We have shown that patients with T2DM who attended a weight management programme and lost weight in a real-world setting have a subsequent improvement in glycaemic control during 3 years of follow-up. These results were from observation of a weight management intervention and the link between the intervention and the resultant clinical effect cannot be deemed to be causal; however, the results were very close to those seen in a large randomized control trial of efficacy 13 
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